MISSION Therapeutics Appoints CFO
This article was originally published in Scrip
MISSION Therapeutics, a drug discovery and development company, has appointed David Luther chief financial officer – effective Oct. 1, 2015. Luther brings more than 25 years' financial and operational experience in healthcare, fast-moving consumer goods (FMCG) and pharmaceutical industries to MISSION. He joins the company from a FMCG business, Spotless Group, where he was vice-president, finance, for commercial and supply chain operations in the UK, Ireland and Italy. Before Spotless, Luther was finance director for the Italian operations of Aptuit and prior to this he was at GlaxoSmithKline plc for 15 years, where he held various senior positions including finance director of neurosciences.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.